Clinical Trials Logo

ER Positive Breast Cancer clinical trials

View clinical trials related to ER Positive Breast Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04504916 Completed - Pancreatic Cancer Clinical Trials

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)

Start date: October 7, 2020
Phase: Phase 2
Study type: Interventional

This is a study evaluating the efficacy, safety, and pharmacokinetics of zilovertamab vedotin in participants with metastatic solid tumors including previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC HER2-negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and platinum-resistant ovarian cancer. The study will evaluate a null hypothesis that the objective response rate (ORR) is ≤5% against the alternative hypothesis that it is ≥20%.

NCT ID: NCT00965939 Completed - Clinical trials for ER-positive Breast Cancer

An Observational Study to Assess Response to Tamoxifen in Breast Cancer Patients

CYPTAMBRUT-2
Start date: February 2009
Phase: N/A
Study type: Observational

CYPTAM-BRUT 2 is a prospective, multicentric study including postmenopausal women receiving tamoxifen for metastatic, locally advanced (stage IIIB/C) or in the neoadjuvant setting for measurable estrogen-receptor positive breast cancers. The primary endpoint is the difference in efficacy of tamoxifen, defined as the objective response rate using RECIST criteria, between women with a normal versus low Tamoxifen Activity Score (TAS) after 3-6 months of tamoxifen use. The TAS score is based on the presence of genetic variations and drug interactions. Secondary endpoints are time to progression, clinical benefit, serum metabolite concentrations, endometrial changes and menopausal symptoms. Patients using tamoxifen in the neoadjuvant setting needs being operated between 4-6 months following the start of tamoxifen.